Aims: Describing the KRAS, NRAS, and BRAF gene status on non-polyp colon cancer stage II-III and their associations with the recurrent sites. Methods: A descriptive design with longitudinal follow-up. 154 patients diagnosed with non-polyp colon cancer stage II-III were recruited at Bach Mai Hospital. All tumors were tested for the status of KRAS, BRAF, and NRAS genes. Results: 43.5% of patients were diagnosed with KRAS gene mutations. NRAS and BRAF gene mutation rates were 2.6% and 5.8%, respectively. The rate of gene mutations in right-sided tumors was higher than that in left-sided tumors (60.0% vs. 42.9%; p=0.034). Stage III was more prevalent in gene mutations than stage II (p=0.054). There was no significant association between recurrent appearance and liver recurrence with KRAS, NRAS, or BRAF gene mutations. Conclusions: KRAS mutations were the most common. Tumor location in the right colon predicted KRAS, BRAF, or NRAS mutation status. Recurrence rates tended to be higher in the mutation group, but the difference was not statistically significant. Mutation status was also not a predictor of liver recurrence. Keywords: Colon cancer; stage II-III; KRAS gene; NRAS gene; BRAF genes; recurrence